Autopsy report · NCT00618917

MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)

“MnSOD longer available during Phase II”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 3 months after it had already started.
• Ran for about 5 years 9 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 10 years 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Joel Greenberger

Sponsor type

University, hospital or other

Conditions

Esophageal; Toxicity

Interventions

Manganese Superoxide Dismutase Plasmid Liposome; carboplatin; paclitaxel; Radiation Therapy

Participants

18

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.